| [1] |
Jemal A, Bray F, Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
|
| [2] |
Early Breast Cancer Trialists'Collaborative Group (EBCTCG),Peto R, Davies C, et al.Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome 100, 000 women in 123 randomised trials[J].Lancet,2012,379(9814):432-444.
|
| [3] |
Pathmanathan N, Balleine RL.Ki67 and proliferation in breast cancer[J].J Clin Pathol,2013,66(6):512-516.
|
| [4] |
Gerdes J, Schwab U, Lemke H, et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Cancer,1983,31(1):13-20.
|
| [5] |
Schluter C, Duchrow M, Wohlenberg C, et al.The cell proliferation-associated antigen of antibody Ki67: a very large,ubiquitous nuclear protein with numerous repeated elements,representing a new kind of cell-cycle-maintaining proteins[J].J Cell Biol,1993,123(3):513-522.
|
| [6] |
Isola J,Helin H, Kallioniemi OP.Immunoelectron-microscopic localization of a proliferation-associated antigen Ki67 in MCF-7 cells[J].Histochem J,1990,22(9):498-506.
|
| [7] |
Heidebrecht HJ, Buck F, Haas K, et al.Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the ‘Ki67'proteins[J].Cell Prolif,1996,29(7):413-425.
|
| [8] |
Beresford MJ, Wilson GD, Makris A.Measuring proliferation in breast cancer: practicalities and applications[J].Breast Cancer Res,2006,8(6):216.
|
| [9] |
Spyratos F, Ferrero-Poüs M, Trassard M, et al.Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value[J].Cancer, 2002,94(8):2151-2159.
|
| [10] |
Yerushalmi R, Woods R, Ravdin PM, et al.Ki67 in breast cancer: prognostic and predictive potential[J].Lancet Oncol,2010,11(2):174-183.
|
| [11] |
Clarke RB.Steroid receptors and proliferation in the human breast[J].Steroids,2003,68(10-13):789-794.
|
| [12] |
Okumura Y, Yamamoto Y, Zhang Z, et al.Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion[J].BMC Cancer,2008,8:287.
|
| [13] |
Shi P, Wang M, Zhang Q, et al.Lipid-rich carcinoma of the breast.A clinicopathological study of 49 cases[J].Tumori,2008,94(3):342-346.
|
| [14] |
Mathieu MC, Rouzier R, Llombart-Cussac A, et al.The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile[J].Eur J Cancer,2004,40(3):342-351.
|
| [15] |
Wang B, Wang X, Wang J, et al.Expression of Ki67 and clinicopathological features in breast cancer[J].Zhonghua Zhong Liu Za Zhi,2014,36(4):273-275.
|
| [16] |
Yamamoto S, Ibusuki M, Yamamoto Y, et al.Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens [ J].Breast Cancer,2013,20(3):262-270.
|
| [17] |
Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
|
| [18] |
Bear HD, Anderson S, Smith RE, et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2006,24(13):2019-2027.
|
| [19] |
von Minckwitz G, Untch M, Blohmer JU, et al.Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J].J Clin Oncol,2012,30(15):1796-1804.
|
| [20] |
Rastogi P, Anderson SJ, Bear HD, et al.Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J].J Clin Oncol,2008,26(5):778-785.
|
| [21] |
Cortazar P, Zhang L, Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J].Lancet,2014,384 (9938):164-172.
|
| [22] |
Dieci MV, Criscitiello C, Goubar A, et al.Prognostic value of tumour-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicentre study[J].Ann Oncol,2014,25(3):611-618.
|
| [23] |
Ellis MJ, Tao Y, Luo J, et al.Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumour characteristics[J].J Natl Cancer Inst,2008,100(19):1380-1388.
|
| [24] |
Lee J, Im YH, Lee SH, et al.Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer [ J].Cancer Chemother Pharmacol,2008,61(4):569-577.
|
| [25] |
Horimoto Y, Arakawa A, Tanabe M, et al.Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer[J].BMC Cancer,2014,14:550.
|
| [26] |
Colleoni M, Viale G, Zahrieh D, et al.Chemotherapy is more effective in patients with breast cancer Not expressing steroid hormone receptors: a study of preoperative treatment[J].Clin Cancer Res,2004,10(19):6622-6628.
|
| [27] |
Fasching PA, Heusinger K, Haeberle L, et al.Ki67,chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J].BMC Cancer,2011,11:486.
|
| [28] |
Sueta A, Yamamoto Y, Hayashi M, et al.Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? [J].Surgery,2014,155(5):927-935.
|
| [29] |
Tan QX, Qin QH, Yang WP,et al.Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy[J].Int J Clin Exp Pathol,2014,7(10):6862-6870.
|
| [30] |
Niikura N, Masuda S, Kumaki N, et al.Prognostic significance of the Ki67 scoring categories in breast cancer subgroups[J].Clin Breast Cancer,2014,14(5):323-329.
|
| [31] |
Yoshioka T, Hosoda M, Yamamoto M, et al.Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer[J].Breast Cancer,2015,22(2):185-191.
|
| [32] |
Perou CM, Sørlie T, Eisen MB, et al.Molecular portraits of human breast tumours [ J].Nature, 2012, 406 (6797):747-752.
|
| [33] |
Faneyte IF, Schrama JG, Peterse JL.Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome[J].Br J Cancer,2003,88(3):406-412.
|
| [34] |
de Azambuja E, Cardoso F, de Castro G Jr, et al.Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients[J].Br J Cancer,2007,96(10):1504-1513.
|
| [35] |
Nishimukai A, Yagi T, Yanai A, et al.High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer[J].Clin Breast Cancer,2015,15(3):204-211.
|
| [36] |
Galimberti V, Manika A, Maisonneuve P,et al.Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease[J].Eur J Surg Oncol,2014,40(10):1203-1208.
|
| [37] |
Falato C, Lorent J,Tani E,et al.Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer[J].Breast Cancer Res Treat,2014,147(2):407-414.
|
| [38] |
Filipits M, Rudas M, Jakesz R, et al.A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors[J].Clin Cancer Res,2011,17(18):6012-6020.
|
| [39] |
Viale G, Giobbie-Hurder A, Regan MM, et al.Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole[J].J Clin Oncol,2008,26(34):5569-5575.
|
| [40] |
董欢, 林燕苹, 应学翔, 等.Ki67、增殖细胞核抗原在不同分子分型乳腺癌组织中的表达及意义[J/CD].中华乳腺病杂志:电子版,2013,7(2):15-20.
|
| [41] |
Evaluation of Genomic Applications in Practice and Prevention(EGAPP) Working Group.Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? [J].Genet Med,2009,11(1):66-73.
|
| [42] |
Polley MY, Leung SC, McShane LM, et al.An international Ki-67 reproductibility study[J].J Natl Cancer Inst,2013,105(24):1897-1906.
|
| [43] |
Mikami Y, Ueno T, Yoshimura K, et al.Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study[J].Cancer Sci,2013,104(11):1539-1543.
|
| [44] |
Gudlaugsson E, Skaland I, Janssen EA, et al.Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer[J].Histopathology,2012,61(6):1134-1144.
|
| [45] |
Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al.A methodology to ensure and improve accuracy of Ki-67 labelling index estimation by automated digital image analysis in breast cancer tissue[J].Breast Cancer Res,2014,16(2):R35.
|